女性性機能不全治療の世界市場2019-2023

◆英語タイトル:Global Female Sexual Dysfunction Treatment Market 2019-2023
◆商品コード:IRTNTR31552
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年6月26日
◆ページ数:108
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、女性性機能不全治療の世界市場について調べ、女性性機能不全治療の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、女性性機能不全治療の市場規模をセグメンテーション別(種類別(非ホルモン療法、ホルモン療法)、)と地域別(アジア、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は女性性機能不全治療の世界市場規模が2019-2023期間中に年平均37%成長すると予測しています。
・サマリー
・レポートの範囲
・女性性機能不全治療の市場状況
・女性性機能不全治療の市場規模
・女性性機能不全治療の市場予測
・女性性機能不全治療の世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(非ホルモン療法、ホルモン療法)
・女性性機能不全治療の顧客状況
・主要地域別市場規模:アジア、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Female Sexual Dysfunction Treatment Market: About this market

Treating female sexual dysfunction linked to a hormonal cause might include estrogen therapy and androgen therapy while non-hormonal cause includes ospemifene (Osphena) and flibanserin (Addyi). Technavio’s female sexual dysfunction treatment market analysis considers sales from both non-hormonal therapy, and hormonal therapy. Our analysis also considers the sales of female sexual dysfunction treatment in Asia, Europe, North America, and ROW. In 2018, the hormonal therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as rising prevalence of chronic diseases and increasing use of drugs that lead to sexual dysfunction in women will play a significant role in the hormonal therapy segment to maintain its market position. Also, our global female sexual dysfunction treatment market report also looks at factors such as increasing prevalence of chronic diseases, growing awareness of female sexual dysfunction, approval and availability of drug to treat hypoactive sexual desire disorder. However, adverse effects of drugs used in female sexual dysfunction treatment, lack of approved drugs, social stigma associated with female sexual dysfunction may hamper the growth of the female sexual dysfunction treatment over the forecast period.

Global Female Sexual Dysfunction Treatment Market: Overview

Increasing prevalence of chronic diseases

Female sexual dysfunctions can be caused due to various chronic diseases such as diabetes. Patients with diabetes may have several clinical conditions, including overweight, hypertension, metabolic syndrome, and atherogenic dyslipidemia, which are risk factors for sexual dysfunction in women. Therefore, rising prevalence of these conditions across the globe is expected to increase the patient pool with a large number of women having sexual dysfunctions, which, in turn, will drive the growth of the global female sexual dysfunction treatment market at a CAGR close to 37% during the forecast period.

Increasing use of drugs causing sexual dysfunctions in women

There are several classes of drugs such as antidepressants, antipsychotics, antiepileptics, and contraceptives, which result in sexual dysfunction in women. Drugs such as beta blockers decrease sexual desire in women. Alpha-adrenergic drugs also reduce sexual desire and arousal in women. Similarly, antidepressants drugs cause sexual difficulties. Furthermore, the majority of sexual dysfunction is caused by dopamine receptor blockade. Thus, the use of such drugs will increase the incidences of sexual dysfunctions in women, thereby increasing the demand for drugs to treat sexual dysfunctions in women.

For the detailed list of factors that will drive the global female sexual dysfunction treatment market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of few major players, the global female sexual dysfunction treatment market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading female sexual dysfunction treatment manufacturers, that include AMAG Pharmaceuticals Inc., Duchesnay Inc., Emotional Brain BV, Novo Nordisk AS, and Sprout Pharmaceuticals Inc.

Also, the female sexual dysfunction treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Non-hormonal therapy – Market size and forecast 2018-2023

Hormonal therapy – Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Increasing R&D for treatment of sexual dysfunctions in women

Safety label changes for female sexual dysfunction therapy

Increasing use of drugs causing sexual dysfunctions in women

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

AMAG Pharmaceuticals Inc.

Duchesnay Inc.

Emotional Brain BV

Novo Nordisk AS

Sprout Pharmaceuticals Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Type – Market share 2018-2023 (%)

Exhibit 18: Comparison by type

Exhibit 19: Non-hormonal therapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Non-hormonal therapy – Year-over-year growth 2019-2023 (%)

Exhibit 21: Hormonal therapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Hormonal therapy – Year-over-year growth 2019-2023 (%)

Exhibit 23: Market opportunity by type

Exhibit 24: Customer landscape

Exhibit 25: Market share by geography 2018-2023 (%)

Exhibit 26: Geographic comparison

Exhibit 27: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 28: North America – Year-over-year growth 2019-2023 (%)

Exhibit 29: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 30: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 31: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 33: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 35: Key leading countries

Exhibit 36: Market opportunity

Exhibit 37: Impact of drivers and challenges

Exhibit 38: Vendor landscape

Exhibit 39: Landscape disruption

Exhibit 40: Vendors covered

Exhibit 41: Vendor classification

Exhibit 42: Market positioning of vendors

Exhibit 43: AMAG Pharmaceuticals Inc. – Vendor overview

Exhibit 44: AMAG Pharmaceuticals Inc. – Business segments

Exhibit 45: AMAG Pharmaceuticals Inc. – Organizational developments

Exhibit 46: AMAG Pharmaceuticals Inc. – Key offerings

Exhibit 47: Duchesnay Inc. – Vendor overview

Exhibit 48: Duchesnay Inc. – Key offerings

Exhibit 49: Emotional Brain BV – Vendor overview

Exhibit 50: Emotional Brain BV – Key offerings

Exhibit 51: Novo Nordisk AS – Vendor overview

Exhibit 52: Novo Nordisk AS – Business segments

Exhibit 53: Novo Nordisk AS – Organizational developments

Exhibit 54: Novo Nordisk AS – Geographic focus

Exhibit 55: Novo Nordisk AS – Segment focus

Exhibit 56: Novo Nordisk AS – Key offerings

Exhibit 57: Sprout Pharmaceuticals Inc. – Vendor overview

Exhibit 58: Sprout Pharmaceuticals Inc. – Key offerings

Exhibit 59: Validation techniques employed for market sizing

Exhibit 60: Definition of market positioning of vendors



【掲載企業】

AMAG Pharmaceuticals Inc., Duchesnay Inc., Emotional Brain BV, Novo Nordisk AS, and Sprout Pharmaceuticals Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[女性性機能不全治療の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆